- Lexaria’s development of its patented DehydraTECH(TM) technology since 2014 has yielded 27 patents in Australia, the United States, the European Union, Japan, India and Mexico with approximately 50 additional patents pending around the world
- Its latest patent, granted in Mexico, applies a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a variety of ready-to-drink consumer retail beverage products
- Lexaria remains committed to advancing its research and expanding the indications and efficacy of its DehydraTECH technology, as it looks to benefit from the CBD industry, projected to be valued at $111.8 billion by 2030, and the cardiovascular drugs market, projected to be valued at $107.8 billion by 2025
Since Lexaria Bioscience (NASDAQ: LEXX) began the development of its industry-leading DehydraTECH(TM) technology back in 2014, the company has remained steadfast in its goal to improve the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes and dementia, among others.
These efforts have yielded 27 granted patents around the world since 2014, with approximately 50 additional patents pending. It also has national filings in over 40 jurisdictions with the highest commercial potential, reflecting the company’s commitment to creating shareholder value and pushing its technology further into the market (https://cnw.fm/10Nnq).
Its latest patent, granted in Mexico under registration #390001, applies to a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a variety of ready-to-drink consumer retail beverage products. Additional claims granted to this patent also include the treatment of neurological diseases such as Parkinson’s disease, Human Immunodeficiency Virus (“HIV”), Alzheimer’s, and Schizophrenia (https://cnw.fm/VO2RC).
Through its four subsidiary companies, Lexaria has explored various sectors such as cannabidiol for hypertension, oral nicotine for reduced risk and antiviral drugs for COVID-19 and other infectious diseases. The progress so far has also allowed them to sub-license its DehydraTECH technology worldwide for delivering fat-soluble active molecules and drugs, thereby increasing the number of people who benefit from this technology and the number of lives impacted by it.
Lexaria remains committed to advancing its studies and expanding the indications and efficacy of its DehydraTECH technology. Through these efforts, it looks to benefit significantly from the CBD industry, projected to be valued at $111.8 billion by 2030 (https://cnw.fm/sX1N7). In addition, Lexaria also looks to capitalize on the growing cardiovascular drugs market, which is projected to be valued at $107.8 billion by 2025, up from $96.1 billion in 2022 (https://cnw.fm/5UqtZ).
As it pushes for the approval of additional patents and the licensing of its technology, the company looks to grow its market share significantly while redefining drug delivery platforms.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.